Academic Journal
View in EDS

Effect of dipeptidyl peptidase-4 inhibitors on postprandial glucagon level in patients with type 2 diabetes mellitus: A systemic review and meta-analysis

Bibliographic Details
Title: Effect of dipeptidyl peptidase-4 inhibitors on postprandial glucagon level in patients with type 2 diabetes mellitus: A systemic review and meta-analysis
Authors: Shangyu Chai, Ruya Zhang, Ye Zhang, Richard David Carr, Yiman Zheng, Swapnil Rajpathak, Linong Ji
Source: Frontiers in Endocrinology, Vol 13 (2022)
Publisher Information: Frontiers Media S.A., 2022.
Publication Year: 2022
Collection: LCC:Diseases of the endocrine glands. Clinical endocrinology
Subject Terms: dipeptidyl peptidase-4 inhibitor, glucagon, hyperglucagonemia, randomized controlled trials, meta-analysis, Diseases of the endocrine glands. Clinical endocrinology, RC648-665
More Details: AimsHyperglucagonemia occurs in the pathogenesis of type 2 diabetes mellitus (T2DM). In this meta-analysis, we summarized the effects of DPP4 inhibitors on glucagon levels in patients with T2DM.Materials and methodsRandomized controlled trials (RCTs) comparing the influence of DPP4 inhibitors on circulating glucagon levels with placebo or other oral antidiabetic drugs (OADs) in patients with T2DM were identified by searches of Medline (PubMed), Embase (Ovid), and CENTER (Cochrane Library). Only studies reporting changes in glucagon level presented as total area under the curve (AUCglucagon) using a meal or oral glucose tolerance test were included. Results were combined using a random-effects model that incorporated potential heterogeneity among the included studies.ResultsA total of 36 RCTs with moderate to high quality were included. Overall, the numbers of T2DM patients included for the meta-analyses comparing DPP4 inhibitors with placebo and other OADs were 4266 and 1652, respectively. Compared to placebo, DPP4 inhibitors significantly reduced circulating glucagon levels (standard mean difference [SMD]: -0.32, 95% CI: -0.40 to -0.24, P0.05). Moreover, DPP4 inhibitors significantly reduced glucagon levels compared to other OADs (SMD: -0.35, 95% CI: -0.53 to -0.16, P
Document Type: article
File Description: electronic resource
Language: English
ISSN: 1664-2392
Relation: https://www.frontiersin.org/articles/10.3389/fendo.2022.994944/full; https://doaj.org/toc/1664-2392
DOI: 10.3389/fendo.2022.994944
Access URL: https://doaj.org/article/2855016960274239a45d46c99f1aaafd
Accession Number: edsdoj.2855016960274239a45d46c99f1aaafd
Database: Directory of Open Access Journals
FullText Text:
  Availability: 0
CustomLinks:
  – Url: https://resolver.ebsco.com/c/xy5jbn/result?sid=EBSCO:edsdoj&genre=article&issn=16642392&ISBN=&volume=13&issue=&date=20221001&spage=&pages=&title=Frontiers in Endocrinology&atitle=Effect%20of%20dipeptidyl%20peptidase-4%20inhibitors%20on%20postprandial%20glucagon%20level%20in%20patients%20with%20type%202%20diabetes%20mellitus%3A%20A%20systemic%20review%20and%20meta-analysis&aulast=Shangyu%20Chai&id=DOI:10.3389/fendo.2022.994944
    Name: Full Text Finder (for New FTF UI) (s8985755)
    Category: fullText
    Text: Find It @ SCU Libraries
    MouseOverText: Find It @ SCU Libraries
  – Url: https://doaj.org/article/2855016960274239a45d46c99f1aaafd
    Name: EDS - DOAJ (s8985755)
    Category: fullText
    Text: View record from DOAJ
    MouseOverText: View record from DOAJ
Header DbId: edsdoj
DbLabel: Directory of Open Access Journals
An: edsdoj.2855016960274239a45d46c99f1aaafd
RelevancyScore: 953
AccessLevel: 3
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 953.466857910156
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Effect of dipeptidyl peptidase-4 inhibitors on postprandial glucagon level in patients with type 2 diabetes mellitus: A systemic review and meta-analysis
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Shangyu+Chai%22">Shangyu Chai</searchLink><br /><searchLink fieldCode="AR" term="%22Ruya+Zhang%22">Ruya Zhang</searchLink><br /><searchLink fieldCode="AR" term="%22Ye+Zhang%22">Ye Zhang</searchLink><br /><searchLink fieldCode="AR" term="%22Richard+David+Carr%22">Richard David Carr</searchLink><br /><searchLink fieldCode="AR" term="%22Yiman+Zheng%22">Yiman Zheng</searchLink><br /><searchLink fieldCode="AR" term="%22Swapnil+Rajpathak%22">Swapnil Rajpathak</searchLink><br /><searchLink fieldCode="AR" term="%22Linong+Ji%22">Linong Ji</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: Frontiers in Endocrinology, Vol 13 (2022)
– Name: Publisher
  Label: Publisher Information
  Group: PubInfo
  Data: Frontiers Media S.A., 2022.
– Name: DatePubCY
  Label: Publication Year
  Group: Date
  Data: 2022
– Name: Subset
  Label: Collection
  Group: HoldingsInfo
  Data: LCC:Diseases of the endocrine glands. Clinical endocrinology
– Name: Subject
  Label: Subject Terms
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22dipeptidyl+peptidase-4+inhibitor%22">dipeptidyl peptidase-4 inhibitor</searchLink><br /><searchLink fieldCode="DE" term="%22glucagon%22">glucagon</searchLink><br /><searchLink fieldCode="DE" term="%22hyperglucagonemia%22">hyperglucagonemia</searchLink><br /><searchLink fieldCode="DE" term="%22randomized+controlled+trials%22">randomized controlled trials</searchLink><br /><searchLink fieldCode="DE" term="%22meta-analysis%22">meta-analysis</searchLink><br /><searchLink fieldCode="DE" term="%22Diseases+of+the+endocrine+glands%2E+Clinical+endocrinology%22">Diseases of the endocrine glands. Clinical endocrinology</searchLink><br /><searchLink fieldCode="DE" term="%22RC648-665%22">RC648-665</searchLink>
– Name: Abstract
  Label: Description
  Group: Ab
  Data: AimsHyperglucagonemia occurs in the pathogenesis of type 2 diabetes mellitus (T2DM). In this meta-analysis, we summarized the effects of DPP4 inhibitors on glucagon levels in patients with T2DM.Materials and methodsRandomized controlled trials (RCTs) comparing the influence of DPP4 inhibitors on circulating glucagon levels with placebo or other oral antidiabetic drugs (OADs) in patients with T2DM were identified by searches of Medline (PubMed), Embase (Ovid), and CENTER (Cochrane Library). Only studies reporting changes in glucagon level presented as total area under the curve (AUCglucagon) using a meal or oral glucose tolerance test were included. Results were combined using a random-effects model that incorporated potential heterogeneity among the included studies.ResultsA total of 36 RCTs with moderate to high quality were included. Overall, the numbers of T2DM patients included for the meta-analyses comparing DPP4 inhibitors with placebo and other OADs were 4266 and 1652, respectively. Compared to placebo, DPP4 inhibitors significantly reduced circulating glucagon levels (standard mean difference [SMD]: -0.32, 95% CI: -0.40 to -0.24, P0.05). Moreover, DPP4 inhibitors significantly reduced glucagon levels compared to other OADs (SMD: -0.35, 95% CI: -0.53 to -0.16, P
– Name: TypeDocument
  Label: Document Type
  Group: TypDoc
  Data: article
– Name: Format
  Label: File Description
  Group: SrcInfo
  Data: electronic resource
– Name: Language
  Label: Language
  Group: Lang
  Data: English
– Name: ISSN
  Label: ISSN
  Group: ISSN
  Data: 1664-2392
– Name: NoteTitleSource
  Label: Relation
  Group: SrcInfo
  Data: https://www.frontiersin.org/articles/10.3389/fendo.2022.994944/full; https://doaj.org/toc/1664-2392
– Name: DOI
  Label: DOI
  Group: ID
  Data: 10.3389/fendo.2022.994944
– Name: URL
  Label: Access URL
  Group: URL
  Data: <link linkTarget="URL" linkTerm="https://doaj.org/article/2855016960274239a45d46c99f1aaafd" linkWindow="_blank">https://doaj.org/article/2855016960274239a45d46c99f1aaafd</link>
– Name: AN
  Label: Accession Number
  Group: ID
  Data: edsdoj.2855016960274239a45d46c99f1aaafd
PLink https://login.libproxy.scu.edu/login?url=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsdoj&AN=edsdoj.2855016960274239a45d46c99f1aaafd
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.3389/fendo.2022.994944
    Languages:
      – Text: English
    Subjects:
      – SubjectFull: dipeptidyl peptidase-4 inhibitor
        Type: general
      – SubjectFull: glucagon
        Type: general
      – SubjectFull: hyperglucagonemia
        Type: general
      – SubjectFull: randomized controlled trials
        Type: general
      – SubjectFull: meta-analysis
        Type: general
      – SubjectFull: Diseases of the endocrine glands. Clinical endocrinology
        Type: general
      – SubjectFull: RC648-665
        Type: general
    Titles:
      – TitleFull: Effect of dipeptidyl peptidase-4 inhibitors on postprandial glucagon level in patients with type 2 diabetes mellitus: A systemic review and meta-analysis
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Shangyu Chai
      – PersonEntity:
          Name:
            NameFull: Ruya Zhang
      – PersonEntity:
          Name:
            NameFull: Ye Zhang
      – PersonEntity:
          Name:
            NameFull: Richard David Carr
      – PersonEntity:
          Name:
            NameFull: Yiman Zheng
      – PersonEntity:
          Name:
            NameFull: Swapnil Rajpathak
      – PersonEntity:
          Name:
            NameFull: Linong Ji
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 10
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-print
              Value: 16642392
          Numbering:
            – Type: volume
              Value: 13
          Titles:
            – TitleFull: Frontiers in Endocrinology
              Type: main
ResultId 1